HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chese-Pond's Mentadent Gum Care, Colgate's Viadent draw warning letters from FDA.

This article was originally published in The Rose Sheet

Executive Summary

CHESE-POND MENTADENT GUM CARE, COLGATE VIADENT DRAW WARNING LETTERS from FDA questioning their plaque and gingivitis claims. Dated March 1, the letters state that the products are unapproved new drugs because their ingredients have not been proven safe and effective for plaque and gingivitis indications nor have they been marketed for a "material time" and to a "material extent." The letters follow a similar warning to Procter & Gamble for its Crest Gum Care toothpaste in October ("The Rose Sheet" Oct. 16, p. 1).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel